O	0	5	Phase
O	6	7	3
O	7	8	,
O	9	13	open
O	13	14	-
O	14	19	label
O	19	20	,
O	21	31	randomized
O	32	37	study
O	38	47	comparing
O	48	49	3
O	49	50	-
O	50	57	monthly
O	58	62	with
O	63	70	monthly
B-intervention	71	80	goserelin
O	81	83	in
O	84	87	pre
O	87	88	-
O	88	98	menopausal
O	99	104	women
O	105	109	with
O	110	118	estrogen
O	119	127	receptor
O	127	128	-
O	128	136	positive
O	137	145	advanced
O	146	152	breast
O	153	159	cancer
O	159	160	.

O	161	168	Monthly
O	169	178	goserelin
O	179	180	3
O	180	181	.
O	181	182	6
O	183	185	mg
O	186	192	dosing
O	193	203	suppresses
O	204	213	estradiol
O	214	215	(
O	215	217	E2
O	217	218	)
O	219	229	production
O	230	233	and
O	234	237	has
O	238	244	proven
O	245	253	efficacy
O	254	256	in
O	257	260	pre
O	260	261	-
O	261	271	menopausal
O	272	277	women
O	278	282	with
O	283	291	estrogen
O	292	300	receptor
O	301	302	(
O	302	304	ER
O	304	305	)
O	305	306	-
O	306	314	positive
O	315	321	breast
O	322	328	cancer
O	328	329	.

O	330	334	This
O	335	338	non
O	338	339	-
O	339	350	inferiority
O	351	356	study
O	357	366	evaluated
O	367	370	the
O	371	379	efficacy
O	380	383	and
O	384	390	safety
O	391	393	of
O	394	395	3
O	395	396	-
O	396	403	monthly
O	404	413	goserelin
O	414	416	10
O	416	417	.
O	417	418	8
O	419	421	mg
O	422	430	compared
O	431	435	with
O	436	443	monthly
O	444	453	goserelin
O	454	455	3
O	455	456	.
O	456	457	6
O	458	460	mg
O	460	461	.

O	462	466	This
O	467	470	was
O	471	472	a
O	473	478	Phase
O	479	480	3
O	480	481	,
O	482	486	open
O	486	487	-
O	487	492	label
O	492	493	,
O	494	505	multicenter
O	506	511	trial
O	511	512	.

B-eligibility	513	516	Pre
I-eligibility	516	517	-
I-eligibility	517	527	menopausal
I-eligibility	528	533	women
I-eligibility	534	538	with
I-eligibility	539	541	ER
I-eligibility	541	542	-
I-eligibility	542	550	positive
I-eligibility	551	559	advanced
I-eligibility	560	566	breast
I-eligibility	567	573	cancer
O	574	578	were
O	579	589	randomized
O	590	592	to
O	593	594	3
O	594	595	-
O	595	602	monthly
O	603	612	goserelin
O	613	615	10
O	615	616	.
O	616	617	8
O	618	620	mg
O	621	623	or
B-control	624	631	monthly
I-control	632	641	goserelin
O	642	643	3
O	643	644	.
O	644	645	6
O	646	648	mg
O	648	649	;
O	650	653	all
O	654	662	patients
O	663	671	received
O	672	683	concomitant
O	684	693	tamoxifen
O	694	695	(
O	695	697	20
O	698	700	mg
O	701	706	daily
O	706	707	)
O	707	708	.

O	709	712	The
O	713	720	primary
O	721	729	endpoint
O	730	733	was
B-outcome-Measure	734	745	progression
I-outcome-Measure	745	746	-
I-outcome-Measure	746	750	free
I-outcome-Measure	751	759	survival
I-outcome-Measure	760	761	(
I-outcome-Measure	761	764	PFS
I-outcome-Measure	764	765	)
I-outcome-Measure	766	770	rate
I-outcome-Measure	771	773	at
I-outcome-Measure	774	776	24
I-outcome-Measure	777	782	weeks
O	782	783	;
O	784	787	non
O	787	788	-
O	788	799	inferiority
O	800	803	was
O	804	806	to
O	807	809	be
O	810	819	confirmed
O	820	822	if
O	823	826	the
O	827	833	entire
O	834	836	95
O	837	838	%
O	839	849	confidence
O	850	858	interval
O	859	860	(
O	860	862	CI
O	862	863	)
O	864	867	for
O	868	871	the
O	872	881	treatment
O	882	892	difference
O	893	896	was
O	897	902	above
O	903	904	-
O	904	906	17
O	906	907	.
O	907	908	5
O	909	910	%
O	910	911	.

O	912	921	Secondary
O	922	931	endpoints
O	932	940	included
B-outcome-Measure	941	950	objective
I-outcome-Measure	951	959	response
I-outcome-Measure	960	964	rate
I-outcome-Measure	965	966	(
I-outcome-Measure	966	969	ORR
I-outcome-Measure	969	970	)
O	970	971	,
B-outcome-Measure	972	977	serum
I-outcome-Measure	978	980	E2
I-outcome-Measure	981	987	levels
O	987	988	,
B-outcome-Measure	989	995	safety
O	995	996	,
O	997	1000	and
B-outcome-Measure	1001	1013	tolerability
O	1013	1014	.

O	1015	1017	In
O	1018	1023	total
O	1023	1024	,
B-total-participants	1025	1028	222
O	1029	1037	patients
O	1038	1042	were
O	1043	1053	randomized
O	1054	1055	(
O	1055	1064	goserelin
O	1065	1067	10
O	1067	1068	.
O	1068	1069	8
O	1070	1072	mg
O	1072	1073	,
O	1074	1075	n
O	1076	1077	=
B-intervention-participants	1078	1081	109
O	1081	1082	;
O	1083	1092	goserelin
O	1093	1094	3
O	1094	1095	.
O	1095	1096	6
O	1097	1099	mg
O	1099	1100	,
O	1101	1102	n
O	1103	1104	=
B-control-participants	1105	1108	113
O	1108	1109	)
O	1109	1110	.

B-outcome	1111	1114	PFS
I-outcome	1115	1119	rate
I-outcome	1120	1122	at
I-outcome	1123	1127	week
I-outcome	1128	1130	24
O	1131	1134	was
B-iv-bin-percent	1135	1137	61
I-iv-bin-percent	1137	1138	.
I-iv-bin-percent	1138	1139	5
I-iv-bin-percent	1140	1141	%
O	1142	1143	(
O	1143	1152	goserelin
O	1153	1155	10
O	1155	1156	.
O	1156	1157	8
O	1158	1160	mg
O	1160	1161	)
O	1162	1165	and
B-cv-bin-percent	1166	1168	60
I-cv-bin-percent	1168	1169	.
I-cv-bin-percent	1169	1170	2
I-cv-bin-percent	1171	1172	%
O	1173	1174	(
O	1174	1183	goserelin
O	1184	1185	3
O	1185	1186	.
O	1186	1187	6
O	1188	1190	mg
O	1190	1191	)
O	1191	1192	;
O	1193	1202	treatment
O	1203	1213	difference
O	1214	1215	(
O	1215	1217	95
O	1218	1219	%
O	1220	1222	CI
O	1222	1223	)
O	1224	1227	was
O	1228	1229	1
O	1229	1230	.
O	1230	1231	3
O	1232	1233	%
O	1234	1235	(
O	1235	1236	-
O	1236	1238	11
O	1238	1239	.
O	1239	1240	4
O	1240	1241	,
O	1242	1244	13
O	1244	1245	.
O	1245	1246	9
O	1246	1247	)
O	1247	1248	,
O	1249	1259	confirming
O	1260	1263	non
O	1263	1264	-
O	1264	1275	inferiority
O	1276	1278	of
O	1279	1288	goserelin
O	1289	1291	10
O	1291	1292	.
O	1292	1293	8
O	1294	1296	mg
O	1297	1305	compared
O	1306	1310	with
O	1311	1320	goserelin
O	1321	1322	3
O	1322	1323	.
O	1323	1324	6
O	1325	1327	mg
O	1327	1328	.

B-outcome	1329	1332	ORR
O	1333	1336	was
B-iv-bin-percent	1337	1339	23
I-iv-bin-percent	1339	1340	.
I-iv-bin-percent	1340	1341	9
I-iv-bin-percent	1342	1343	%
O	1344	1345	(
O	1345	1354	goserelin
O	1355	1357	10
O	1357	1358	.
O	1358	1359	8
O	1360	1362	mg
O	1362	1363	)
O	1364	1367	and
B-cv-bin-percent	1368	1370	26
I-cv-bin-percent	1370	1371	.
I-cv-bin-percent	1371	1372	9
I-cv-bin-percent	1373	1374	%
O	1375	1376	(
O	1376	1385	goserelin
O	1386	1387	3
O	1387	1388	.
O	1388	1389	6
O	1390	1392	mg
O	1392	1393	)
O	1393	1394	;
O	1395	1404	treatment
O	1405	1415	difference
O	1416	1417	(
O	1417	1419	95
O	1420	1421	%
O	1422	1424	CI
O	1424	1425	)
O	1426	1429	was
O	1430	1431	-
O	1431	1432	3
O	1432	1433	.
O	1433	1434	0
O	1435	1436	%
O	1437	1438	(
O	1438	1439	-
O	1439	1441	15
O	1441	1442	.
O	1442	1443	5
O	1443	1444	,
O	1445	1446	9
O	1446	1447	.
O	1447	1448	7
O	1448	1449	)
O	1449	1450	.

O	1451	1453	At
O	1454	1458	week
O	1459	1461	24
O	1461	1462	,
B-outcome	1463	1467	mean
I-outcome	1468	1473	serum
I-outcome	1474	1476	E2
I-outcome	1477	1491	concentrations
O	1492	1496	were
O	1497	1504	similar
O	1505	1507	in
O	1508	1511	the
O	1512	1521	goserelin
O	1522	1524	10
O	1524	1525	.
O	1525	1526	8
O	1527	1529	mg
O	1530	1533	and
O	1534	1543	goserelin
O	1544	1545	3
O	1545	1546	.
O	1546	1547	6
O	1548	1550	mg
O	1551	1557	groups
O	1558	1559	(
B-iv-cont-mean	1559	1561	20
I-iv-cont-mean	1561	1562	.
I-iv-cont-mean	1562	1563	3
I-iv-cont-mean	1564	1566	pg
I-iv-cont-mean	1566	1567	/
I-iv-cont-mean	1567	1569	mL
O	1570	1573	and
B-cv-cont-mean	1574	1576	24
I-cv-cont-mean	1576	1577	.
I-cv-cont-mean	1577	1578	8
I-cv-cont-mean	1579	1581	pg
I-cv-cont-mean	1581	1582	/
I-cv-cont-mean	1582	1584	mL
O	1584	1585	,
O	1586	1598	respectively
O	1598	1599	)
O	1599	1600	.

O	1601	1602	A
O	1603	1610	regimen
O	1611	1613	of
O	1614	1615	3
O	1615	1616	-
O	1616	1623	monthly
O	1624	1633	goserelin
O	1634	1636	10
O	1636	1637	.
O	1637	1638	8
O	1639	1641	mg
O	1642	1654	demonstrated
O	1655	1658	non
O	1658	1659	-
O	1659	1670	inferiority
O	1671	1679	compared
O	1680	1684	with
O	1685	1692	monthly
O	1693	1702	goserelin
O	1703	1704	3
O	1704	1705	.
O	1705	1706	6
O	1707	1709	mg
O	1710	1713	for
O	1714	1717	PFS
O	1718	1722	rate
O	1723	1725	at
O	1726	1728	24
O	1729	1734	weeks
O	1734	1735	,
O	1736	1740	with
O	1741	1748	similar
O	1749	1764	pharmacodynamic
O	1765	1768	and
O	1769	1775	safety
O	1776	1784	profiles
O	1784	1785	,
O	1786	1788	in
O	1789	1792	pre
O	1792	1793	-
O	1793	1803	menopausal
O	1804	1809	women
O	1810	1814	with
O	1815	1817	ER
O	1817	1818	-
O	1818	1826	positive
O	1827	1833	breast
O	1834	1840	cancer
O	1840	1841	.
